# Successful Treatment of Adalimumab-Induced Pustular Psoriasis With Guselkumab in a Patient With Hidradenitis Suppurativa

## TL;DR

A patient with hidradenitis suppurativa developed pustular psoriasis after adalimumab treatment but improved significantly with guselkumab.

## Contribution

Demonstrates successful treatment of adalimumab-induced pustular psoriasis using guselkumab, an IL-23 inhibitor.

## Key findings

- Adalimumab therapy led to a diffuse pustular rash in a patient with hidradenitis suppurativa.
- Switching to guselkumab resulted in significant improvement within a week and continued resolution at follow-up.
- TNF-alpha inhibitors may cause pustular psoriasis, and IL-23 inhibitors like guselkumab may be a better alternative.

## Abstract

Pustular psoriasis is a rare and severe form of psoriasis, characterized by the presence of desquamative plaques with pustules on an erythematous base. Psoriasis is thought to result from plasmacytoid dendritic cell (PDC)-mediated T-cell activation, which stimulates keratinocyte proliferation via type 1 interferon signaling. Studies suggest that TNF-alpha inhibition can paradoxically enhance interferon-alpha activity, leading to the development of pustular psoriasis in some cases. A 58-year-old patient with hidradenitis suppurativa began adalimumab therapy. One month later, she presented with a diffuse pustular rash. A punch biopsy revealed pustular psoriasis with negative direct immunofluorescence (DIF) and periodic acid-Schiff (PAS) stain. Despite treatment with topical steroids, the rash worsened. Her therapy was switched to guselkumab, alongside continued topical steroids. This resulted in significant improvement within a week, with continued resolution at the one-month follow-up. Psoriasis and hidradenitis suppurativa are driven by chronic inflammation involving TNF-alpha and the IL-23/IL-17 axis. While TNF-alpha inhibitors like adalimumab reduce inflammation, paradoxical reactions like pustular psoriasis can occur due to enhanced interferon-alpha activity. In patients on this therapy who develop a new-onset diffuse pustular rash, an index of suspicion for this condition should be maintained. TNF-alpha inhibitors should be discontinued if pustular psoriasis develops, with IL-23 inhibitors providing a viable alternative.